Tempest Therapeutics
Price & Volume
Stats
See more52W Range | $1.50-$12.23 |
Market Cap | $22.6M |
Shares Short | 401,128 |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$5.70 |
News
See moreYahoo Finance • 17 days ago
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
Yahoo Finance • last month
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
Yahoo Finance • 3 months ago
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
About
CEO | Dr. Matthew Angel Ph.D. |
CFO | Mr. Nicholas Maestas |
Address | 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 4 |